HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.

Abstract
Nitric oxide-releasing non-steroidal antiinflammatory drugs (NO-NSAIDs) are safer than NSAIDs due to their ability to reduce gastric toxicity. We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines. All the lines were positive for COX-1 protein and mRNA, as evaluated by Western blot and RT-PCR, respectively, while only one was positive for COX-2. The cytostatic and cytocidal activity was determined by sulforhodamine B assay and evaluated according to Monks' model. Cytostatic activity was observed after a 24-h drug exposure and 50% growth inhibition was reached at concentrations ranging from 165 to 250 micro M in all cell lines, whereas with aspirin the IC50 was never reached, even at the maximum concentration tested (500 micro M), and was independent of COX-1 or COX-2 status. Cytocidal activity was observed only at the highest concentrations and persisted for a long time after drug removal. Flow cytometric analysis showed that the NO-aspirin compound induced a persistent accumulation of cells in G2-M phase in all the cell lines after at least 48 h exposure. Specifically, the block pertained mainly to G2 phase, whereas mitotic index was not affected at all. Our results indicate that NCX 4016 has an in vitro cytostatic activity superior to that of its parental aspirin compound, which makes it a potentially important tumor preventive agent. Furthermore, the cytocidal effect observed at the highest concentrations and the induction of a specific block in G2 phase renders it a promising candidate for drug combination treatments.
AuthorsAnna Tesei, Luca Ricotti, Paola Ulivi, Laura Medri, Dino Amadori, Wainer Zoli
JournalInternational journal of oncology (Int J Oncol) Vol. 22 Issue 6 Pg. 1297-302 (Jun 2003) ISSN: 1019-6439 [Print] Greece
PMID12738997 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticarcinogenic Agents
  • Isoenzymes
  • Membrane Proteins
  • Platelet Aggregation Inhibitors
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • PTGS1 protein, human
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • nitroaspirin
  • Aspirin
Topics
  • Adenocarcinoma (pathology)
  • Anticarcinogenic Agents (pharmacology)
  • Aspirin (analogs & derivatives, pharmacology)
  • Cell Cycle (drug effects)
  • Cell Division (drug effects)
  • Cell Survival (drug effects)
  • Colonic Neoplasms (pathology)
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Gene Expression Regulation, Enzymologic (drug effects)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Isoenzymes (genetics, metabolism)
  • Kinetics
  • Membrane Proteins
  • Platelet Aggregation Inhibitors (pharmacology)
  • Prostaglandin-Endoperoxide Synthases (genetics, metabolism)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: